UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 or 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of June, 2020

Commission File Number: 001-38452

 

 

MEREO BIOPHARMA GROUP PLC

(Translation of registrant’s name into English)

 

 

4th Floor, One Cavendish Place,

London, W1G 0QF, United Kingdom

(Address of principal executive office)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  ☒            Form 40-F  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

 

 

 


The following exhibits are furnished herewith:

 

Exhibit 99.1    Press release issued by Mereo BioPharma Group plc “Result of Annual General Meeting” dated June 29, 2020.
Exhibit 99.2    Press release issued by Mereo BioPharma Group plc “Result of General Meeting” dated June 30, 2020.
Exhibit 99.3    Press release issued by Mereo BioPharma Group plc “Mereo BioPharma Strengthens Management Team; Appoints John Lewicki, PhD, as Chief Scientific Officer and Ann Kapoun, PhD, as SVP of Translational Research and Development” dated June 30, 2020.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: June 30, 2020

 

MEREO BIOPHARMA GROUP PLC
By:  

/s/ Charles Sermon

  Name: Charles Sermon
  Title:   General Counsel
Mereo BioPharma (NASDAQ:MREO)
Historical Stock Chart
From Aug 2020 to Sep 2020 Click Here for more Mereo BioPharma Charts.
Mereo BioPharma (NASDAQ:MREO)
Historical Stock Chart
From Sep 2019 to Sep 2020 Click Here for more Mereo BioPharma Charts.